BIIB vs XBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and XBIO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- XBIO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 5 TA indicator(s) are bullish while XBIO’s TA Score has 4 bullish TA indicator(s).
- BIIB’s TA Score: 5 bullish, 5 bearish.
- XBIO’s TA Score: 4 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +2.26% price change this week, while XBIO (@Biotechnology) price change was +14.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.83%. For the same industry, the average monthly price growth was -1.25%, and the average quarterly price growth was -8.10%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.96%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -9.88%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
XBIO is expected to report earnings on Mar 18, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+4.83% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.96% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | XBIO | BIIB / XBIO | |
| Capitalization | 31.3B | 4.32M | 724,873% |
| EBITDA | 2.04B | -4.36M | -46,733% |
| Gain YTD | -22.103 | -29.825 | 74% |
| P/E Ratio | 26.95 | N/A | - |
| Revenue | 9.84B | 2.52M | 389,853% |
| Total Cash | 1.05B | 6.84M | 15,351% |
| Total Debt | 7.34B | 153K | 4,796,078% |
BIIB | XBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 17 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 67 | 94 | |
PRICE GROWTH RATING 1..100 | 65 | 87 | |
P/E GROWTH RATING 1..100 | 96 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XBIO's Valuation (17) in the Biotechnology industry is significantly better than the same rating for BIIB (88). This means that XBIO’s stock grew significantly faster than BIIB’s over the last 12 months.
XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100). This means that XBIO’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's SMR Rating (67) in the Biotechnology industry is in the same range as XBIO (94). This means that BIIB’s stock grew similarly to XBIO’s over the last 12 months.
BIIB's Price Growth Rating (65) in the Biotechnology industry is in the same range as XBIO (87). This means that BIIB’s stock grew similarly to XBIO’s over the last 12 months.
BIIB's P/E Growth Rating (96) in the Biotechnology industry is in the same range as XBIO (100). This means that BIIB’s stock grew similarly to XBIO’s over the last 12 months.
| BIIB | XBIO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 70% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 57% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 52% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 53% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 82% |
| Advances ODDS (%) | 15 days ago 54% | 1 day ago 84% |
| Declines ODDS (%) | 13 days ago 69% | 18 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 56% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 66% | 1 day ago 85% |
BIIB and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with OGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then OGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +0.24% | ||
| OGN - BIIB | 49% Loosely correlated | +4.26% | ||
| AMGN - BIIB | 46% Loosely correlated | +0.80% | ||
| NVS - BIIB | 44% Loosely correlated | +0.44% | ||
| PFE - BIIB | 42% Loosely correlated | +0.57% | ||
| AZN - BIIB | 36% Loosely correlated | +0.52% | ||
More | ||||
XBIO and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, XBIO has been loosely correlated with SYRE. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XBIO jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To XBIO | 1D Price Change % | ||
|---|---|---|---|---|
| XBIO | 100% | +0.27% | ||
| SYRE - XBIO | 34% Loosely correlated | +3.82% | ||
| VXRT - XBIO | 29% Poorly correlated | +11.60% | ||
| CDTX - XBIO | 28% Poorly correlated | -2.37% | ||
| VKTX - XBIO | 27% Poorly correlated | +3.80% | ||
| AUTL - XBIO | 27% Poorly correlated | +4.51% | ||
More | ||||